Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort.
Teira R, Diaz-Cuervo H, Aragão F, Muñoz J, Galindo P, Merino M, de la Fuente B, Sepúlveda MA, Domingo P, García J, Castaño M, Ribera E, Geijo P, Romero A, Peraire J, Deig E, Roca B, Martínez E, Estrada V, Montero M, Berenguer J, Espinosa N. Teira R, et al. Among authors: castano m. HIV Res Clin Pract. 2021 Jun;22(3):78-85. Epub 2021 Aug 19. HIV Res Clin Pract. 2021. PMID: 34410219
Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study.
Podzamczer D, Martínez E, Domingo P, Ferrer E, Viciana P, Curto J, Pérez-Elías MJ, Ocampo A, Santos I, Knobel H, Estrada V, Negredo E, Segura F, Portilla J, Ribera E, Galindo J, Antela A, Carmena J, Castaño M, The Toral Study Group. Podzamczer D, et al. Among authors: castano m. Curr HIV Res. 2012 Dec;10(8):673-8. doi: 10.2174/157016212803901428. Curr HIV Res. 2012. PMID: 23061598
Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
Blanco JR, Caro-Murillo AM, Castaño MA, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Riera M, Pulido F, Vera F, Romero-Palacios A, Aguirrebengoa K, Portilla J, Ferrer P, Pedrol E. Blanco JR, et al. Among authors: castano ma. HIV Clin Trials. 2013 Sep-Oct;14(5):204-15. doi: 10.1310/hct1403-204. HIV Clin Trials. 2013. PMID: 24144897
Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
Pedrol E, Caro-Murillo AM, Castaño MA, Riera M, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Pulido F, Romero-Palacios A, Aguirrebengoa K, Vera F, Ferrer P, Blanco Ramos JR. Pedrol E, et al. Among authors: castano ma. HIV Clin Trials. 2015 Jan-Feb;16(1):43-8. doi: 10.1179/1528433614Z.0000000001. Epub 2015 Jan 28. HIV Clin Trials. 2015. PMID: 25777189
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group. Troya J, et al. Among authors: castano m. PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. eCollection 2016. PLoS One. 2016. PMID: 27727331 Free PMC article.
Redefining therapeutic success in HIV patients: an expert view.
Antela A, Rivero A, Llibre JM, Moreno S; RET Group. Antela A, et al. J Antimicrob Chemother. 2021 Sep 15;76(10):2501-2518. doi: 10.1093/jac/dkab168. J Antimicrob Chemother. 2021. PMID: 34077524 Free PMC article. Review.
Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort.
Teira R, Diaz-Cuervo H, Aragão F, Castaño M, Romero A, Roca B, Montero M, Galindo MJ, Muñoz-Sánchez MJ, Espinosa N, Peraire J, Martínez E, de la Fuente B, Domingo P, Deig E, Merino MD, Geijo P, Estrada V, Sepúlveda MA, García J, Berenguer J, Currán A. Teira R, et al. Among authors: castano m. Infect Dis Ther. 2022 Jun;11(3):1177-1192. doi: 10.1007/s40121-022-00630-y. Epub 2022 Apr 11. Infect Dis Ther. 2022. PMID: 35399147 Free PMC article.
Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.
López-Cortés LF, Castaño MA, López-Ruz MA, Rios-Villegas MJ, Hernández-Quero J, Merino D, Jiménez-Aguilar P, Marquez-Solero M, Terrón-Pernía A, Tellez-Pérez F, Viciana P, Orihuela-Cañadas F, Palacios-Baena Z, Vinuesa-Garcia D, Fajardo-Pico JM, Romero-Palacios A, Ojeda-Burgos G, Pasquau-Liaño J. López-Cortés LF, et al. Among authors: castano ma. PLoS One. 2016 Feb 12;11(2):e0148924. doi: 10.1371/journal.pone.0148924. eCollection 2016. PLoS One. 2016. PMID: 26872331 Free PMC article.
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy.
Rivero-Juarez A, Lopez-Cortes LF, Castaño M, Merino D, Marquez M, Mancebo M, Cuenca-Lopez F, Jimenez-Aguilar P, Lopez-Montesinos I, Lopez-Cardenas S, Collado A, Lopez-Ruz MA, Omar M, Tellez F, Perez-Stachowski X, Hernandez-Quero J, Girón-Gonzalez JA, Fernandez-Fuertes E, Rivero A; HERACLES cohort study team of the Grupo de Estudio de Hepatitis Virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Rivero-Juarez A, et al. Among authors: castano m. Eur J Clin Microbiol Infect Dis. 2017 Mar;36(3):487-494. doi: 10.1007/s10096-016-2822-6. Epub 2016 Oct 27. Eur J Clin Microbiol Infect Dis. 2017. PMID: 27787664 Free PMC article.
261 results